{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T23:12:46Z","timestamp":1726009966272},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/rhu.0b013e3181886064","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T07:10:47Z","timestamp":1222845047000},"page":"278-280","source":"Crossref","is-referenced-by-count":12,"title":["Rituximab for Severe Refractory Pediatric Wegener Granulomatosis"],"prefix":"10.1097","volume":"14","author":[{"given":"Aarat M.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J. A.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210207","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s004670050043","article-title":"Wegener granulomatosis in children and young adults. A case study of ten patients.","volume":"14","author":"Stegmayr","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"R2-6-20210207","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-3476(05)83482-1","article-title":"Wegener granulomatosis in children and adolescents: clinical presentation and outcome.","volume":"122","author":"Rottem","year":"1993","journal-title":"J Pediatr"},{"key":"R3-6-20210207","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients.","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"R4-6-20210207","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.","volume":"16","author":"de Groot","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R5-6-20210207","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/art.21146","article-title":"Methotrexate for Wegener's granulomatosis: what is the evidence?","volume":"52","author":"Specks","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R6-6-20210207","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-6-20210207","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.V1091965","article-title":"Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement.","volume":"10","author":"Nowack","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R8-6-20210207","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.","volume":"15","author":"Booth","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R9-6-20210207","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","article-title":"Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.","volume":"54","author":"Stone","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R10-6-20210207","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1523-1755.2004.00534.x","article-title":"Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients.","volume":"65","author":"Schmitt","year":"2004","journal-title":"Kidney Int"},{"key":"R11-6-20210207","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5414\/CNP64485","article-title":"Autologous stem cell transplantation of treatment-resistant systemic vasculitis\u2013a single center experience and review of the literature.","volume":"64","author":"Kotter","year":"2005","journal-title":"Clin Nephrol"},{"key":"R12-6-20210207","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ndt\/gfh763","article-title":"Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients.","volume":"20","author":"Schmitt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R13-6-20210207","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.","volume":"93","author":"Jayne","year":"2000","journal-title":"Qjm"},{"key":"R14-6-20210207","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R15-6-20210207","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"R16-6-20210207","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment.","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R17-6-20210207","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.0902-4441.2003.00196.x","article-title":"Monoclonal antibodies in the treatment of autoimmune cytopenias.","volume":"72","author":"Robak","year":"2004","journal-title":"Eur J Haematol"},{"key":"R18-6-20210207","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study.","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R19-6-20210207","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","article-title":"Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.","volume":"107","author":"Bennett","year":"2006","journal-title":"Blood"},{"key":"R20-6-20210207","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/14740338.4.3.599","article-title":"Reactivation of hepatitis B virus with rituximab.","volume":"4","author":"Tsutsumi","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"R21-6-20210207","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/ndt\/gfh599","article-title":"Effective therapeutic use of rituximab in refractory Wegener's granulomatosis.","volume":"20","author":"Ferraro","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R22-6-20210207","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R23-6-20210207","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R24-6-20210207","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R25-6-20210207","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.2005.048900","article-title":"Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?","volume":"65","author":"Flossmann","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R26-6-20210207","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations.","volume":"65","author":"Aries","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00124743-200810000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T16:40:23Z","timestamp":1631896823000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-200810000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e3181886064","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}